BioPorto A/S announced its 2025 annual results showing total revenues of DKK 40.3 million, an 11% increase from 2024, driven by strong growth in NGAL biomarker sales, especially in the US market. The company reported an adjusted EBITDA loss of DKK 76.5 million but remains within its financial guidance. Key achievements include securing US commercial availability for ProNephro AKI and advancing clinical studies. For 2026, BioPorto projects 20-45% revenue growth and aims to achieve positive cash flow by the second half of 2027, supported by strategic financing and market expansion plans.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
